# Prevest Denpro share price today (Prevest Denpro Ltd, NSE: PREVEST)

> Prevest Denpro share price today: ₹376.35 at the BSE close on 30 October 2026, down 28.2% in a year. Prevest Denpro (NSE: PREVEST) trades at a P/E of 24.8 and has closed between ₹358.60 and ₹510.00 over the past 52 weeks. > Prevest Denpro Ltd's earnings have grown faster than its share price. Earnings per share grew +12.9% in a year while the price moved −28.2%. PREVEST · Medical Equipment · data as of 30 October 2026. Page: https://www.sectoralpha.in/stocks/prevest-denpro-ltd

Sector Alpha also publishes a daily newsletter that explains one Indian stock at a time: https://newsletter.sectoralpha.in/?utm_source=sectoralpha&utm_medium=ai_text&utm_campaign=llms

## Key numbers

- Business trend: Getting better, from fewer quarters than usual
- Price: ₹376.35 (−28.2% in a year)
- P/E: 24.8× (lower than 85% of the last 4.4 years)
- Revenue (Dec 2025): ₹18.4 Cr (+23.0% on a year ago)
- Profit (Dec 2025): ₹5.2 Cr (+15.5% on a year ago)
- Operating margin: 33.9% (−0.6 points on a year ago)
- ROCE: 25%, FY25
- Profit that came in as cash: 72%, last 3 years

The main question: yearly earnings per share moved +12.9% while the share price moved −28.2%. ## What is the Prevest Denpro share price today? Prevest Denpro Ltd's share price was ₹376.35 at the close on 30 October 2026. It has been falling for 15 weeks. That is 8.4% below its average price over the last 200 trading days. In the last 52 weeks it traded between ₹359 and ₹510, and at that close it sat 12% of the way up from that low. Over the past 13 weeks it has done better than the NIFTY 500, and it has stayed ahead for 6 weeks in a row. Over the last 5.1 years the share price moved +100% while the NIFTY 500 moved +45%, so it is ahead of the index over that whole period. The chart above shows the 13-week comparison for every week. This page treats a rise as over when the price closes below its 200-day average on two Fridays in a row. ## What are Prevest Denpro's latest quarterly results? For October to December 2025 (the quarter ended 31 December 2025), Prevest Denpro reported revenue of ₹18.4 crore, up 23.0% from ₹14.9 crore a year earlier, and a profit of ₹5.15 crore, up 15.5% from ₹4.46 crore. ### Prevest Denpro results: October to December 2025 against a year earlier

| Measure | October to December 2025 | October to December 2024 | Change |
| --- | --- | --- | --- |
| Revenue | ₹18.4 crore | ₹14.9 crore | +23.0% |
| Profit | ₹5.15 crore | ₹4.46 crore | +15.5% |
| Earnings per share | ₹4.29 | ₹3.72 | +15.3% |
| Operating margin | 33.9% | 34.4% | −0.6 points |

The next results, for January to March 2026, were due by 30 May 2026: listed companies must publish quarterly results within 60 days of the quarter's end (the January to March quarter comes with the full-year accounts). This page shows them once our weekly data update has read them. (From the company's reported quarterly results (quarter ended 31 December 2025). Revenue and profit in ₹ crore.)

## What is the Prevest Denpro share price history? Prevest Denpro closed at ₹376.35 on 30 October 2026, down 28.2% from ₹524.45 a year earlier (31 October 2025) and up 54.9% over five years. Its highest weekly close since October 2021 was ₹668.80 on 12 July 2024. ### Prevest Denpro share price: then and now

| When | Close | Change to 30 Oct 2026 |
| --- | --- | --- |
| 1 week ago · 23 Oct 2026 | ₹377.55 | −0.3% |
| 1 month ago · 1 Oct 2026 | ₹377.05 | −0.2% |
| 6 months ago · 30 Apr 2026 | ₹440.00 | −14.5% |
| 1 year ago · 31 Oct 2025 | ₹524.45 | −28.2% |
| 3 years ago · 27 Oct 2023 | ₹437.20 | −13.9% |
| 5 years ago · 29 Oct 2021 | ₹243.00 | +54.9% |
| Earliest and lowest weekly close in our records · 1 Oct 2021 | ₹188.55 | +99.6% |
| Highest weekly close since October 2021 · 12 Jul 2024 | ₹668.80 | −43.7% |
| 52-week high (weekly close) · 7 Nov 2025 | ₹510.00 | −26.2% |
| 52-week low (weekly close) · 27 Mar 2026 | ₹358.60 | +4.9% |

Weekly closing prices. Each change is the move from that price to the 30 Oct 2026 close. A day's intraday high or low can go beyond these weekly closes. (266 weekly closes from 1 October 2021 to 30 October 2026.)

## What is the latest news on Prevest Denpro? 30 Oct 2026: Prevest Denpro closed at ₹376.35, down 0.3% on the week and down 0.2% on the month. Results for October to December 2025: Revenue up 23.0% and profit up 15.5% on a year earlier. ## What dividend does Prevest Denpro pay? The NSE corporate-actions record has no dividend for Prevest Denpro since its first NSE close in our records (1 October 2021), so this page cannot show amounts per share. Yes. Prevest Denpro Ltd paid out 7% of its profit as dividends in FY25, and it paid a dividend in 3 of its last 7 reported years. (From the NSE corporate-actions record, read 4 November 2026.)

## Which stock lists is Prevest Denpro on? Prevest Denpro is not on any of our India lists this week. ## Is Prevest Denpro profitable? Prevest Denpro Ltd earned ₹5.2 Cr of net profit in the Dec 2025 quarter, +15.5% on the same quarter a year earlier. That is the 6th quarter in a row of profit growth. Full-year FY25 profit was ₹18.0 Cr. Over 6 years profit has grown 34.8% a year on average. That is 28.0% of the quarter's revenue. The same quarter a year earlier earned ₹4.5 Cr. For the full year, FY25 profit was ₹18.0 Cr (+12.5% on the year before). Why profit moved: revenue changed +23.0% on a year earlier and the margin moved −0.6 percentage points. Sales did the work, and the margin was about flat. On average over the last four quarters, profit changed +17.5% and revenue +17.4%. Profit and revenue are moving at about the same pace. ## How much revenue does Prevest Denpro make, and is it growing? Prevest Denpro Ltd reported ₹18.4 Cr of revenue in the Dec 2025 quarter, +23.0% on the same quarter a year earlier. That is the 6th quarter in a row with growth on the year before. Over 6 years it has grown 22.1% a year on average. The last full year, FY25, came in at ₹63.0 Cr. The last four reported quarters add to ₹71.3 Cr. FY25 revenue was ₹63.0 Cr, +12.5% on the year before. Recent pace: the last four quarters grew +17.4% on average, against 22.1% a year over the longer run, so this year is growing slower than its own long-run rate. Is growth speeding up? Revenue over the last 12 months grew +17.3%, against +14.9% a year over the last 8 quarters (stabilising); profit over the last 12 months grew +17.0%, against +11.5% a year (accelerating). ## How much of every ₹100 of sales does Prevest Denpro keep? Prevest Denpro Ltd's operating margin was 33.9% in the Dec 2025 quarter, 0.6 percentage points lower than the same quarter a year ago. Across 7 years it has been between 20.0% and 40.0%. The latest quarter is within that range. Why the margin moved: operating margin changed −0.6 percentage points on the year while gross margin changed +1.3 points. So the drop came mostly from the gross margin, which means input costs and prices charged. ## Is Prevest Denpro's profit turning into cash? Over the last 3 years, 72% of Prevest Denpro Ltd's reported profit came in as cash from its operations, so most of the profit is real cash. In FY25 it brought in ₹15.0 Cr of operating cash against ₹18.0 Cr of profit. After ₹2.0 Cr of spending on assets, ₹13.0 Cr was left over as free cash. Cash-flow figures here are yearly, because quarterly cash statements are not published, so this section changes once a year. Why 72% of profit came in as cash: the cash cycle got 189 days longer between FY20 and FY25, so more of each rupee of profit waits in the business before it arrives. What to look at next: less of the profit turns into cash than it should, and the cash cycle is 189 days longer. The next section looks at where the cash is stuck. ## Where does Prevest Denpro's cash go? Prevest Denpro Ltd's cash cycle, the days between paying suppliers and getting paid by customers, was 211 days in FY25, up from 22 days in FY20. It spent ₹19.0 Cr on assets over the last 3 years. Customers take 45 days to pay, and stock sits for 208 days on average. At FY25 sales of ₹63.0 Cr, each day of that cycle ties up about ₹0.2 Cr, so roughly ₹36.0 Cr is tied up in the business at any time. FY25: customers took 45 days to pay and stock sat for 208 days, about 6.8 months of sales sitting as stock, for a full cycle of 211 days, longer than FY20's 22. The full loop: cash goes out to suppliers and production on day 0. Stock sits for 208 days. Customers pay about 45 days after that. Suppliers are paid at 42 days. Together that makes the 211-day cycle. Spending on assets: ₹19.0 Cr over the last 3 years, against ₹4.0 Cr of depreciation (the yearly wear and tear on existing assets). So it is building well beyond replacing what wears out. Work still in progress is ₹0.0 Cr (FY25): assets paid for that are not earning yet. In short: cash is getting stuck in the daily cycle, so watch the cycle more than the profit. ## What is Prevest Denpro's P/E ratio, and how does it compare with its own history? Prevest Denpro Ltd's P/E is 24.8×, near the low end of its own history: it has been lower only 15% of the time. Its usual P/E (the middle reading) is 32.5×, over 4.4 years of weekly prices. This compares the share price with the company’s own past. It does not say what the business is worth. Why the multiple is where it is: over the past year earnings per share moved +12.9% while the price moved −28.2%. Earnings did better than the price, which pulled the multiple down within its own range. Where the price move came from: over 3 years the price moved −4.9% a year; about +16.4% a year came from earnings growth and about −21.3 percentage points from the multiple (the market paying less). The split is approximate (price return minus earnings growth). It shows how much of the move came from the market paying a different multiple. In short: the multiple is low against its own past, so the earnings trend underneath matters more than the multiple. ## Is the Prevest Denpro business getting better or worse? Prevest Denpro Ltd's business is getting better. Profit growth hit its low 6 quarters ago at −8.8% and has recovered to +15.5% (from single-quarter figures), with ROCE falling at 25.0%. This is based on 9 quarters of 3 measures, with some gaps. Why it matters: a lasting rise from a low is what this page is built to show. The return figures here are yearly, not quarterly. They show level and direction only; they can support the growth lines but never decide the reading alone. This reading has some gaps: at least one line is short, or the return line is not the quarterly series, so treat it with a little more caution. ## How much does Prevest Denpro earn on its capital? Prevest Denpro Ltd earned a ROCE of 25% in FY25. We cannot compare its return on capital used with its cost of capital from the data we have. It comes from a 28.6% net margin and 0.56× asset turnover (sales divided by assets). Why the return is what it is (FY25): a 28.6% net margin × 0.56× asset turnover × 1.07× leverage (assets divided by equity) ≈ 17.1% on equity. The margin does most of the work; borrowing plays a small part, so this return is earned, not borrowed. ## Does Prevest Denpro have too much debt? Prevest Denpro Ltd had ₹0.0 Cr of borrowings against ₹106 Cr of equity in FY25, so its debt is 0.00× its equity. Over 5 years borrowings went from ₹2.0 Cr to ₹0.0 Cr. Over the last 3 of those years it spent ₹19.0 Cr on assets. The spending on assets is being paid for from cash, not new debt. ## What is the Prevest Denpro shareholding pattern? No group of Prevest Denpro Ltd's owners changed its stake by a full percentage point over the last two years. Domestic institutions moved +0.1 points over the same period, to 0.8%. This uses the four owner groups that companies report every quarter; nothing is guessed between filings. Over the last two years: Foreign institutions: +0.3 points over 8 quarters, to 0.7%; Domestic institutions: +0.1 points over 8 quarters, to 0.8%; Promoters: +0.0 points over 8 quarters, to 73.6%. ## How far is Prevest Denpro from balance-sheet trouble? For Prevest Denpro Ltd, the Z-score is not available, so we say so rather than guess one. It estimates how far the balance sheet is from trouble; it is not a forecast of failure. The debt, cash-flow and return sections show the balance-sheet figures we do have, each with its own date. ## How does Prevest Denpro rank in its industry? 64.4 out of 100, rank 5 of 6 in Medical Equipment, with 43% of the evidence available. It is provisional, so it is ranked below companies with full evidence. Prevest Denpro Ltd scores 64.4 out of 100 against the 6 companies it is compared with in Medical Equipment, ranking 5. Some evidence is missing, so the score is pulled toward the middle on purpose. The three scored parts add up to the total exactly: 23.5 + 23.6 + 17.3 = 64.4 (no relative-strength reading this week; its 20 points are shared across the other three). This is the same number shown on the industry page; it is worked out once for the whole group and read here. What would change it: The score would fall if profit growth turns negative or margins stop improving while the share price lags its sector. ## Which companies is Prevest Denpro compared with? Prevest Denpro ranks 5 of 6 Medical Equipment companies on the 4-Factor Sector Score, with 64.4 out of 100. 1. [Laxmi Dental Ltd](https://www.sectoralpha.in/stocks/laxmi-dental-ltd) LAXMIDENTL · quiet · Evidence leans up · 68% evidence 53.3 out of 100 Growth Capital Valuation Relative How the score adds up Growth & earnings 20.4/35 · Revenue 16.7% · Profit 34.8% · Operating margin change 1 points · 100% evidence Capital efficiency 14.5/25 · ROCE 15% · Operating margin 19% · 100% evidence Valuation 10.9/20 · P/E 28.1× · PEG n/a · 15% evidence Relative strength 7.5/20 · Lead over its industry n/a · Lead over NIFTY 500 -13.9% · 1 year -43.5% · 25% evidence · 0 of 12 weeks ahead Exact sum: 20.4 + 14.5 + 10.9 + 7.5 = 53.3 · What this means: The evidence is balanced: no factor stands out, so another reported quarter is needed before the picture is clearer. 2. [Vasa Denticity Ltd](https://www.sectoralpha.in/stocks/vasa-denticity-ltd) DENTALKART · breaking out · Evidence leans down · 75% evidence 35.7 out of 100 Growth Capital Valuation Relative How the score adds up Growth & earnings 14.3/35 · Revenue 17.9% · Profit -30.2% · Operating margin change 1.1 points · 100% evidence Capital efficiency 4.6/25 · ROCE 7% · Operating margin 6.1% · 100% evidence Valuation 6.9/20 · P/E 65× · PEG n/a · 50% evidence Relative strength 9.9/20 · Lead over its industry n/a · Lead over NIFTY 500 -0.8% · 1 year -27.7% · 25% evidence · 8 of 12 weeks ahead Exact sum: 14.3 + 4.6 + 6.9 + 9.9 = 35.7 · What this means: The evidence is balanced: no factor stands out, so another reported quarter is needed before the picture is clearer. 3. [Poly Medicure Ltd](https://www.sectoralpha.in/stocks/poly-medicure-ltd) POLYMED · quiet · Most evidence points down · 100% evidence 31.9 out of 100 Growth Capital Valuation Relative How the score adds up Growth & earnings 12.5/35 · Revenue 18.4% · Profit -12.3% · Operating margin change -2 points · 100% evidence Capital efficiency 13.3/25 · ROCE 12.5% · Operating margin 24% · 100% evidence Valuation 5.2/20 · P/E 45.9× · PEG 3.87 · 100% evidence Relative strength 0.9/20 · Lead over its industry -19.9% · Lead over NIFTY 500 -4.6% · 1 year -27.5% · 100% evidence · 6 of 12 weeks ahead Exact sum: 12.5 + 13.3 + 5.2 + 0.9 = 31.9 · What this means: The evidence is balanced: no factor stands out, so another reported quarter is needed before the picture is clearer. 4. [Tarsons Products Ltd](https://www.sectoralpha.in/stocks/tarsons-products-ltd) TARSONS · losing its lead · Most evidence points down · 75% evidence 29.5 out of 100 Growth Capital Valuation Relative How the score adds up Growth & earnings 5.8/35 · Revenue 10.6% · Profit -59.7% · Operating margin change -3.5 points · 100% evidence Capital efficiency 6.6/25 · ROCE 4.6% · Operating margin 23.6% · 100% evidence Valuation 5.4/20 · P/E 131× · PEG n/a · 50% evidence Relative strength 11.7/20 · Lead over its industry n/a · Lead over NIFTY 500 22.2% · 1 year 0.7% · 25% evidence · 10 of 12 weeks ahead Exact sum: 5.8 + 6.6 + 5.4 + 11.7 = 29.5 · What this means: The evidence is balanced: no factor stands out, so another reported quarter is needed before the picture is clearer. 5. Prevest Denpro Ltd this page PREVEST · Too little evidence to rank firmly · 43% evidence 64.4 out of 100 Growth Capital Valuation Relative How the score adds up Growth & earnings 23.5/43.75 · Revenue 17.3% · Profit 17% · Operating margin change -0.6 points · 53% evidence Capital efficiency 23.6/31.25 · ROCE 25.2% · Operating margin 33.9% · 57% evidence Valuation 17.3/25 · P/E 24.8× · PEG n/a · 50% evidence Relative strength: no reading this week · its 20 points are shared across the other three Exact sum: 23.5 + 23.6 + 17.3 = 64.4 (no relative-strength reading this week; its 20 points are shared across the other three) · What this means: Some evidence is missing, so the score is pulled toward the middle on purpose. 6. [Hemant Surgical Industries Ltd](https://www.sectoralpha.in/stocks/hemant-surgical-industries-ltd) breaking out · Too little evidence to rank firmly · 48% evidence 60.8 out of 100 Growth Capital Valuation Relative How the score adds up Growth & earnings 23.0/35 · Revenue 57.2% · Profit 52.9% · Operating margin change -1 points · 48% evidence Capital efficiency 15.6/25 · ROCE 18.9% · Operating margin 9% · 95% evidence Valuation 9.7/20 · P/E 49.2× · PEG n/a · 15% evidence Relative strength 12.5/20 · Lead over its industry n/a · Lead over NIFTY 500 67.5% · 1 year n/a · 25% evidence · 8 of 12 weeks ahead Exact sum: 23 + 15.6 + 9.7 + 12.5 = 60.8 · What this means: Some evidence is missing, so the score is pulled toward the middle on purpose. Missing figures are not scored as bad. They lower the confidence and pull the final score toward the middle. Relative strength counts only when the company has a reading for this week; with no reading, that factor is left out and its 20 points are shared across the other three in proportion. PEG is not shown when the ratio cannot mean anything: the company must be making a profit, its price-to-earnings must be positive, and its three-year earnings growth must fall between 5% and 60%. Dividing a price multiple by a loss, or by growth measured off a tiny base, produces a number that looks precise and tells you nothing. Under relative strength, one mark per week shows the last 12 weeks: a mark is filled where the company led NIFTY 500 by 5% or more over the 13 weeks ending that week, which is the same test used everywhere on this site. Price stage places the company on the same six-step path the industry is placed on (basing, turning, breaking out, leader, fading, asleep), read from how many weeks running it has led NIFTY 500 and whether that lead is growing or shrinking. It describes where the share price stands, not the direction of earnings, and it is not a recommendation; it is left blank for a company whose weekly history is too short or too stale to read. The figures in this ranking come from the industry comparison: results through the Jun 2026 quarter, and the P/E at that quarter's end. The sections above use the latest weekly price, so a P/E or return there can differ a little from the one here. The stage words in this ranking (such as losing its lead or breaking out) describe the lead over the index, not the price phase in the price section. Related companies: [Medical Equipment](https://www.sectoralpha.in/sectors/medical-equipment), all 6 compared on one page. ## Which companies are close to Prevest Denpro in size? Prevest Denpro is the 6th largest of 6 Medical Equipment companies on Sector Alpha by market value (scores of 30 October 2026). Just above it: Poly Medicure, Tarsons Products, Laxmi Dental, Hemant Surgical Industries and Vasa Denticity. It is the smallest. ### Medical Equipment companies close in size

1. [Poly Medicure Ltd](https://www.sectoralpha.in/stocks/poly-medicure-ltd) ₹14,692 crore
2. [Tarsons Products Ltd](https://www.sectoralpha.in/stocks/tarsons-products-ltd) ₹1,548 crore
3. [Laxmi Dental Ltd](https://www.sectoralpha.in/stocks/laxmi-dental-ltd) ₹977 crore
4. [Hemant Surgical Industries Ltd](https://www.sectoralpha.in/stocks/hemant-surgical-industries-ltd) ₹834 crore
5. [Vasa Denticity Ltd](https://www.sectoralpha.in/stocks/vasa-denticity-ltd) ₹754 crore
6. Prevest Denpro Ltd ₹510 crore

[All 6 Medical Equipment companies, largest first](https://www.sectoralpha.in/sectors/medical-equipment#all-companies)

### Companies close in size in other industries

1. [Pansari Developers Ltd](https://www.sectoralpha.in/stocks/pansari-developers-ltd) ₹454 crore · Construction - Housing
2. [Focus Lighting & Fixtures Ltd](https://www.sectoralpha.in/stocks/focus-lighting-fixtures-ltd) ₹452 crore · Capital Goods - Electric General
3. Prevest Denpro Ltd ₹452 crore
4. [Modi Naturals Ltd](https://www.sectoralpha.in/stocks/modi-naturals-ltd) ₹451 crore · Edible Oils, Agro Processing
5. [Mcleod Russel India Ltd](https://www.sectoralpha.in/stocks/mcleod-russel-india-ltd) ₹450 crore · Tea

## What else do people ask about Prevest Denpro? ### What were Prevest Denpro's latest quarterly results? Prevest Denpro Ltd reported revenue of ₹18.4 Cr and net profit of ₹5.2 Cr for the Dec 2025 quarter. Revenue rose 23.0% and profit rose 15.5% compared with a year earlier. Earnings per share were ₹4.29. The operating margin was 33.9%, 0.6 percentage points lower than a year earlier (as of 30 October 2026). ### What is Prevest Denpro's market cap? Prevest Denpro Ltd's market capitalisation is ₹510 Cr at a share price of ₹376.35. Market cap is the share price times the number of shares, so it changes whenever the price moves (as of 30 October 2026). ### How is Prevest Denpro performing? Prevest Denpro Ltd's share price has been falling for 15 weeks. In its latest quarter, revenue rose 23.0% and profit rose 15.5% compared with a year earlier. Over the past 13 weeks it has done better than the NIFTY 500, for 6 weeks running (as of 30 October 2026). ### Will Prevest Denpro's share price go up? This page does not forecast Prevest Denpro Ltd's share price. What it shows instead: the share price is ₹376.35, and it has been falling for 15 weeks. Its P/E of 24.8× is higher than 15% of its own last 4 years (as of 30 October 2026). ### Where is Prevest Denpro in its business cycle? Prevest Denpro Ltd's FY25 operating margin was 35.0%, against a 7-year range of 20.0% to 40.0%: the middle of its own range, neither a peak nor a low. The latest quarter was 33.9%. Comparing margins with a company's own long history is a good way to see where it is in its cycle (as of 30 October 2026). ### What could break the Prevest Denpro story? The main question: yearly earnings per share moved +12.9% while the share price moved −28.2%. On price, this page treats a rise as over when the share price closes below its 200-day average on two Fridays in a row (as of 30 October 2026). ### Is Prevest Denpro a stock worth studying right now? What the numbers show: Prevest Denpro Ltd's earnings have grown faster than its share price. Earnings per share grew +12.9% in a year while the price moved −28.2%. The main open question: whether the price catches up with earnings that have already grown. Every number on this page is worked out by code from the published figures, with no forecasts and no price opinions (as of 30 October 2026). This is research, not advice. We’re not SEBI-registered.